| Market Capitalization (Millions $) |
29 |
| Shares
Outstanding (Millions) |
390 |
| Employees |
142 |
| Revenues (TTM) (Millions $) |
35 |
| Net Income (TTM) (Millions $) |
-123 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Sangamo Therapeutics Inc is a clinical-stage biotechnology company headquartered in Richmond, California, United States.
The company specializes in developing genetic therapies for diseases caused by genetic defects or deficiencies.
Sangamo Therapeutics Inc aims to cure genetic diseases utilizing gene and cellular therapies.
The company's innovative approach involves editing the genetic code of cells to fix the root cause of genetic disorders.
The company's proprietary technology, called zinc finger nuclease (ZFN), enables precise and targeted cutting and editing of the genome.
Sangamo Therapeutics employs various methods and innovative technologies to ensure the delivery of the edited genetic material to the targeted cells.
Sangamo Therapeutics has a wide range of product candidates under different developmental stages, including gene therapies for hemophilia, lysosomal storage disorders, and sickle cell anemia.
Additionally, the company has a pipeline of CAR-T (Chimeric Antigen Receptor T-cell) candidates to treat different cancer types.
Sangamo Therapeutics has established partnerships with other leading pharmaceutical companies, including Pfizer, Novartis, and Sanofi, to co-develop and commercialize its gene therapy products.
Overall, Sangamo Therapeutics Inc is at the forefront of genetic engineering, and it strives to revolutionize the future of medicine by developing gene therapies to provide long-lasting and durable benefits to patients with genetic diseases.
Company Address: 501 Canal Blvd. Richmond 94804 CA
Company Phone Number: 970-6000 Stock Exchange / Ticker: NASDAQ SGMO
|
0.000%
7.5% 
0 %